MX2021007572A - Anticuerpo anti-pd-1 humanizado y uso del mismo. - Google Patents
Anticuerpo anti-pd-1 humanizado y uso del mismo.Info
- Publication number
- MX2021007572A MX2021007572A MX2021007572A MX2021007572A MX2021007572A MX 2021007572 A MX2021007572 A MX 2021007572A MX 2021007572 A MX2021007572 A MX 2021007572A MX 2021007572 A MX2021007572 A MX 2021007572A MX 2021007572 A MX2021007572 A MX 2021007572A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- antigen
- nucleic acid
- acid sequence
- binding fragment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un anticuerpo monoclonal humanizado recombinante contra la proteína de muerte celular programada-1 (PD-1) o un fragmento de unión a antígeno del mismo útil para la inmunoterapia de tumores o cáncer. También se proporciona una secuencia de ácido nucleico que codifica el anticuerpo o un fragmento de unión a antígeno del mismo, un vector que contiene la secuencia de ácido nucleico, una composición farmacéutica y un kit.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811573605.4A CN111349162A (zh) | 2018-12-21 | 2018-12-21 | 人源化抗pd-1抗体及其用途 |
PCT/CN2019/126594 WO2020125712A1 (zh) | 2018-12-21 | 2019-12-19 | 人源化抗pd-1抗体及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021007572A true MX2021007572A (es) | 2021-10-13 |
Family
ID=71102488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021007572A MX2021007572A (es) | 2018-12-21 | 2019-12-19 | Anticuerpo anti-pd-1 humanizado y uso del mismo. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220002412A1 (es) |
EP (1) | EP3901172A4 (es) |
JP (1) | JP7358478B2 (es) |
KR (1) | KR20210106514A (es) |
CN (2) | CN111349162A (es) |
AU (1) | AU2019409184B2 (es) |
BR (1) | BR112021012299A2 (es) |
CA (1) | CA3124276A1 (es) |
MX (1) | MX2021007572A (es) |
TW (1) | TWI750554B (es) |
WO (1) | WO2020125712A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230026446A (ko) * | 2020-06-19 | 2023-02-24 | 사이노셀테크 엘티디. | 재조합 항-pd-1 단일클론 항체를 위한 안정한 제형 |
CN114761434B (zh) * | 2020-09-30 | 2023-06-27 | 苏州沙砾生物科技有限公司 | Pd-1抗体及其制备方法与应用 |
CN113336847B (zh) * | 2021-02-03 | 2022-08-23 | 上海莱馥医疗科技有限公司 | 一种抗pd-1抗体 |
CN114573696B (zh) * | 2022-03-10 | 2023-07-25 | 深圳市元谷生物科技有限公司 | 一种结合程序性死亡受体1(pd-1)的抗体及其用途 |
CN116036266A (zh) * | 2022-12-28 | 2023-05-02 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗结肠癌患者的药物中的用途 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT1068241E (pt) | 1998-04-02 | 2007-11-19 | Genentech Inc | Variantes de anticorpos e respectivos fragmentos |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
AU2011203119C1 (en) * | 2005-05-09 | 2018-06-14 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
SI2439273T1 (sl) * | 2005-05-09 | 2019-05-31 | Ono Pharmaceutical Co., Ltd. | Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki |
SG10201804945WA (en) * | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
MX2018001227A (es) * | 2015-07-30 | 2018-03-26 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas. |
KR20180054824A (ko) * | 2015-09-29 | 2018-05-24 | 셀진 코포레이션 | Pd-1 결합 단백질 및 이의 사용 방법 |
MX2018003936A (es) | 2015-10-02 | 2018-07-06 | Symphogen As | Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones. |
US10894830B2 (en) | 2015-11-03 | 2021-01-19 | Janssen Biotech, Inc. | Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses |
CN106699889A (zh) * | 2015-11-18 | 2017-05-24 | 礼进生物医药科技(上海)有限公司 | 抗pd-1抗体及其治疗用途 |
NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
CN106519034B (zh) * | 2016-12-22 | 2020-09-18 | 鲁南制药集团股份有限公司 | 抗pd-1抗体及其用途 |
CN108840932B (zh) * | 2018-04-28 | 2022-03-29 | 中国科学院微生物研究所 | 一种pd-1特异性抗体及其抗肿瘤应用 |
-
2018
- 2018-12-21 CN CN201811573605.4A patent/CN111349162A/zh active Pending
-
2019
- 2019-12-19 KR KR1020217022647A patent/KR20210106514A/ko not_active Application Discontinuation
- 2019-12-19 MX MX2021007572A patent/MX2021007572A/es unknown
- 2019-12-19 JP JP2021536399A patent/JP7358478B2/ja active Active
- 2019-12-19 BR BR112021012299-0A patent/BR112021012299A2/pt unknown
- 2019-12-19 CA CA3124276A patent/CA3124276A1/en active Pending
- 2019-12-19 TW TW108146721A patent/TWI750554B/zh active
- 2019-12-19 EP EP19898443.7A patent/EP3901172A4/en active Pending
- 2019-12-19 AU AU2019409184A patent/AU2019409184B2/en active Active
- 2019-12-19 CN CN201980081406.8A patent/CN113166260B/zh active Active
- 2019-12-19 WO PCT/CN2019/126594 patent/WO2020125712A1/zh unknown
-
2021
- 2021-06-21 US US17/353,617 patent/US20220002412A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020125712A1 (zh) | 2020-06-25 |
JP7358478B2 (ja) | 2023-10-10 |
EP3901172A4 (en) | 2023-01-11 |
TWI750554B (zh) | 2021-12-21 |
CA3124276A1 (en) | 2020-06-25 |
EP3901172A1 (en) | 2021-10-27 |
CN113166260A (zh) | 2021-07-23 |
CN111349162A (zh) | 2020-06-30 |
US20220002412A1 (en) | 2022-01-06 |
CN113166260B (zh) | 2023-11-14 |
AU2019409184B2 (en) | 2024-05-23 |
BR112021012299A2 (pt) | 2021-09-08 |
AU2019409184A1 (en) | 2021-07-22 |
KR20210106514A (ko) | 2021-08-30 |
TW202039568A (zh) | 2020-11-01 |
JP2022514962A (ja) | 2022-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021007572A (es) | Anticuerpo anti-pd-1 humanizado y uso del mismo. | |
MX2021011697A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123. | |
CR20200467A (es) | Agentes anticuerpos anti-cd25 | |
MX2019008221A (es) | Anticuerpo anti-gpc3. | |
JOP20180042A1 (ar) | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام | |
WO2020082209A8 (zh) | 抗cldn18.2抗体及其用途 | |
WO2021097365A3 (en) | Antigen-binding proteins targeting shared neoantigens | |
NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
MX2021013850A (es) | Anticuerpo contra tigit y uso del mismo. | |
AU2019433019A8 (en) | Antibodies binding CD40 and uses thereof | |
SA519401032B1 (ar) | (pd-1) جسم مضاد لموت الخلية المبرمج1 واستخدامه | |
ZA202200906B (en) | Anti-her2/anti-4-1bb bispecific antibody and use thereof | |
WO2015191590A3 (en) | Combination therapies targeting tumor-associated stroma or tumor cells and microtubules | |
MX2021003168A (es) | Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico. | |
CR20220061A (es) | Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células | |
PH12020551451A1 (en) | Anti-cd25 for tumour specific cell depletion | |
EP3947447A4 (en) | ANTI-CD73, ANTI-PD-L1 ANTIBODIES AND TUMOR TREATMENT CHEMOTHERAPY | |
SG11201806597XA (en) | ANTIBODY AGAINST EGFRvIII AND USE THEREOF | |
MX2022002363A (es) | Sistema receptor de antígeno quimérico y usos de este. | |
MX2022003191A (es) | Terapias de combinacion con anticuerpos entpd2 y cd73. | |
MX2021015356A (es) | Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos. | |
WO2015191583A3 (en) | Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase | |
MX2021002077A (es) | Nuevas composiciones de anticuerpos para la inmunoterapia contra el cáncer. | |
WO2015191615A3 (en) | Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents | |
EP4062934A4 (en) | COMPOSITION FOR PREVENTING OR TREATING CANCER WITH ANTI-CD300C MONOCLONAL ANTIBODIES |